2021.09.02
Cure Genetics announced today that Dr. Patrick Liu, as co-founder and board member, has joined the company as president of the group. Dr. Liu will be responsible for overall operation management of the company, including construction and expansion of innovative technology platforms, strategic layout of projects and pipelines, translational, clinical and business development, in order to further accelerate the translation of science research into product development, as well as global partnership efforts.
Dr. Liu graduated from Peking Union Medical College with a doctorate degree in medicine, and has served as CSO Livzon Pharmaceutical Group, VP and chief strategy officer of Jiangsu Hengrui Group, global VP at Teva, and R&D director of Roche/Genentech and Tanox. He is also a visiting professor at University of Maryland School of Pharmacy. Dr. Liu is one of the first scientists to apply monoclonal antibody technology in the R&D of biologics. He has led more than 100 biologics research and development projects, successfully established several innovative drug technology platforms, and promoted the successful launch of 12 important biologics in various therapeutic areas, including oncology, neurology, respiratory, immunology and infection.
“Dr. Patrick Liu has rich experience in global biopharmaceutical R&D and executive management of multinational companies, with forward-looking strategic international vision and industry insight,” said Dr. Yuanyuan Xu, Chairman of Cure Genetics, “I believe Dr. Liu will effectively build up the company's product pipeline, talent pool and continue to help the team develop and grow, which is important to achieve the company's strategic goals.
Dr. Patrick Liu said, “Cure Genetics's self-developed innovative platform technology has huge potential for integration and application with distinct competitive advantages in the global marketplace. I believe the Company is at a critical inflection point of technology-to-product transformation, and it is making great progress in the field of innovative drugs. We hope to work together with industry colleagues to promote the translation and application of our core technology in new drug development.